Mesoblast (Mesoblast) Receivables Turnover : 0.00 (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Mesoblast Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Mesoblast's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Mesoblast's average Accounts Receivable for the three months ended in Dec. 2023 was $1.80 Mil.

Mesoblast Receivables Turnover Historical Data

The historical data trend for Mesoblast's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Receivables Turnover Chart

Mesoblast Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Receivables Turnover

Get a 7-Day Free Trial

4.00

26.16

5.55

4.83

3.33

Mesoblast Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Receivables Turnover	Get a 7-Day Free Trial															1.15	0.99	1.02	-	-

Competitive Comparison of Mesoblast's Receivables Turnover

For the Biotechnology subindustry, Mesoblast's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mesoblast's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Mesoblast's Receivables Turnover falls into.

Mesoblast Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Mesoblast's Receivables Turnover for the fiscal year that ended in Jun. 2023 is calculated as

	Receivables Turnover (A: Jun. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Jun. 2023 )	/ (	(Accounts Receivable (A: Jun. 2022 )	+	Accounts Receivable (A: Jun. 2023 ))	/	count )
=	7.501	/ (	(2.224	+	2.276)	/	2 )
=	7.501	/	2.25
=	3.33

Mesoblast's Receivables Turnover for the quarter that ended in Dec. 2023 is calculated as

	Receivables Turnover (Q: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2023 )	/ (	(Accounts Receivable (Q: Sep. 2023 )	+	Accounts Receivable (Q: Dec. 2023 ))	/	count )
=	0	/ (	(0	+	1.804)	/	1 )
=	0	/	1.804
=	N/A

Mesoblast (OTCPK:MEOBF) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Mesoblast Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Mesoblast's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast (Mesoblast) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

MESO:USA LWB:Germany MSB:Australia

Address

Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.